Janssen Sciences Ireland Uc

Medivir Ab

Tibotec Pharmaceuticals Ltd.

Janssen Sciences Ireland Unlimited Company

Janssen Products, LP

Pierre Jean-Marie Raboisson

Tim Hugo Maria Jonckers

Abdellah Tahri

Koen Vandyck

Lili Hu

Wim Van De Vreken

David Craig McGowan

Sandrine Marie Helene Vendeville

Bart Rudolf Romanie Kesteleyn

Herman Augustinus De Kock

Werner Constant Johan Embrechts

Wim Gaston Verschueren

Ludwig Paul Cooymans

Jérôme Émile Georges Guillemont

Geerwin Yvonne Paul Haché

Geert Rombouts

David Craig Mc Gowan

Maxime Francis Jean-Marie Ghislain Canard

Steven Maurice Van Hoof

This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), Ris a Calkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, Calkyl, or Calkoxy, the carbon of Rbonded to the amine in the 4-position of the quinazoline is in (R)-configuration, Ris hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, Ris hydrogen or deuterium, Ris hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, Cheterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, Cheterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, Ris hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R, R, Rand Ris not hydrogen. 

2,4-diaminoquinazoline derivatives and medical uses thereof

Inhibitors of HCV replication of formula (I) and the salts and stereoisomers thereof, wherein

Macrocyclic inhibitors of hepatitis C virus

Inhibitors of HBV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R-R, B and Z have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy. 

4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B

Compounds of the formula I: including any possible stereoisomers thereof, wherein: 

Uracyl spirooxetane nucleosides

HIV inhibitory compounds of formula: salts and stereoisomers thereof, wherein n is 1, 2 or 3;

1,5,6,-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-inflective agents

Growing community of inventors

Rosieres, Belgium

Pierre Jean-Marie Raboisson